NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
25 April 2025
| Name: | OPTHEA LIMITED (OPT) | ||||||
| ISIN: | AU000000OPT2 | ||||||
| Date of Listing: | 18 April 1991 | ||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently suspended from quotation on the Australian Securities Exchange and its securities cannot be traded on-market.Legal Status: (updated monthly)
ACN: 006 340 567ABN: 32 006 340 567
Registration Date: 17 October 1984
Capital Gains Tax (CGT) Status: (updated at least quarterly)
The securities in this entity, in our opinion, are of little or no value. We have made that assessment by reference to the circumstances leading to a suspension and/or delisting, the length of a suspension, share trading history and last on-market share price, most recent financial and cash flow statements, prospects (including likelihood of re-financing), and other factors including in particular whether the entity is in external administration. If you are seeking to crystallise a capital loss on your securities, that process can be easily and quickly initiated at our online Worthless Shares facility here: https://www.delisted.com.au/sell-worthless-and-other-securities/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| OPTHEA LIMITED | 14/12/2015 | |
| CIRCADIAN TECHNOLOGIES LIMITED | 14/12/2015 |
Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail
Expand this box to read and print
Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 13/04/2025 |
The company has announced a 65% workforce reduction to preserve cash following the termination of its COAST and ShORe Phase 3 clinical trials. The reduction will be effective from May 1, 2025, with one-off costs of approximately $4.5M and monthly employee costs of $1M. Opthea estimates unaudited cash and cash equivalents of $100M at the end of March 2025. | 10/04/2025 |
The company's securities were suspended due to breach of Listing Rule 12.2, and will continue suspension until compliance is confirmed. | 31/03/2025 |
The company discontinues wet AMD trials, including COAST and ShORe, due to accelerated topline results and failure to meet primary endpoint. Opthea and DFA Investors agree to terminate both trials. | 31/03/2025 |
The company has announced the results of its COAST Phase 3 clinical trial. The trial did not meet the primary endpoint of mean change in best corrected visual acuity from baseline to week 52. | 24/03/2025 |
The securities of Opthea Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPT, pending the release of an announcement regarding clinical trial results. | 19/03/2025 |
The following Options of Opthea Limited will be reinstated to quotation from the commencement of trading on Thursday, 18 July 2024: OPTOB | 17/07/2024 |
The options of Opthea Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Thursday, 18 July 2024. The suspension only applies to OPT's options (ASX: OPTOB) and does not apply to any other quoted securities of OPT. | 11/07/2024 |
The suspension of trading in the options (ASX: OPTOA) of Opthea Limited will be lifted immediately. | 22/09/2023 |
The options of Opthea Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Friday, 22 September 2023. The suspension only applies to OPT's options and does not apply to any other quoted securities of OPT. | 15/09/2023 |
name changed from Circadian Technologies Limited | 14/12/2015 |
Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 13/04/2025 |
The company has announced a 65% workforce reduction to preserve cash following the termination of its COAST and ShORe Phase 3 clinical trials. The reduction will be effective from May 1, 2025, with one-off costs of approximately $4.5M and monthly employee costs of $1M. Opthea estimates unaudited cash and cash equivalents of $100M at the end of March 2025. | 10/04/2025 |
The company's securities were suspended due to breach of Listing Rule 12.2, and will continue suspension until compliance is confirmed. | 31/03/2025 |
The company discontinues wet AMD trials, including COAST and ShORe, due to accelerated topline results and failure to meet primary endpoint. Opthea and DFA Investors agree to terminate both trials. | 31/03/2025 |
The company has announced the results of its COAST Phase 3 clinical trial. The trial did not meet the primary endpoint of mean change in best corrected visual acuity from baseline to week 52. | 24/03/2025 |
The securities of Opthea Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPT, pending the release of an announcement regarding clinical trial results. | 19/03/2025 |
The following Options of Opthea Limited will be reinstated to quotation from the commencement of trading on Thursday, 18 July 2024: OPTOB | 17/07/2024 |
The options of Opthea Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Thursday, 18 July 2024. The suspension only applies to OPT's options (ASX: OPTOB) and does not apply to any other quoted securities of OPT. | 11/07/2024 |
The suspension of trading in the options (ASX: OPTOA) of Opthea Limited will be lifted immediately. | 22/09/2023 |
The options of Opthea Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Friday, 22 September 2023. The suspension only applies to OPT's options and does not apply to any other quoted securities of OPT. | 15/09/2023 |
name changed from Circadian Technologies Limited | 14/12/2015 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 04/04/2019 | Megan Baldwin | -667,000 | $0.660 | $440,220 |
| 24/04/2017 | Michael Sistenich | 200,178 | $0.930 | $186,166 |
| 24/05/2013 | Robert Klupacs | 5,000 | $0.250 | $1,250 |
| 22/05/2013 | Robert Klupacs | 42,000 | $0.260 | $10,920 |
| 16/05/2013 | Tina McMeckan | 30,000 | $0.251 | $7,539 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Jeremy Levin | Chairman | 12/10/2020 |
| Frederic Guerard | CEO | 27/10/2023 |
| Tom Reilly | CFO | 28/10/2024 |
| Julia Haller | Independent Director | 01/06/2021 |
| Anshul Thakral | Non Exec Director | 09/06/2023 |
| Kathy Connell | Non Exec Director | 15/11/2024 |
| Sujal Shah | Non Exec Director | 04/04/2024 |
| Lawrence Gozlan | Non Exec Director | 24/07/2020 |
| Susan Orr | Director | 21/04/2022 |
| Quinton Oswald | Director | 21/04/2022 |
| Karen Adams | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Megan Baldwin | Executive Director | 24/02/2014 | 15/11/2024 |
| Daniel Geffken | CFO | 09/09/2024 | 28/10/2024 |
| Peter Lang | CFO | 27/10/2023 | 09/09/2024 |
| Daniel Spiegelman | Independent Director | 10/09/2020 | 04/04/2024 |
| Timothy Morris | CFO | 24/10/2022 | 27/10/2023 |
| Michael Sistenich | Non Exec Director | 30/11/2015 | 09/06/2023 |
| Judith Robertson | Independent Director | 01/06/2021 | 03/01/2022 |
| Michael Tonroe | CFO | 19/05/2014 | 24/06/2021 |
| Geoffrey Kempler | Chairman | 30/11/2015 | 12/10/2020 |
| Dominique Fisher | Non Exec Chairman | 04/08/2005 | 30/11/2015 |
| Tina McMeckan | Non Exec Director | 19/01/2008 | 30/11/2015 |
| Russell Howard | Non Exec Director | 03/12/2013 | 30/11/2015 |
| Mark Pryn | CFO | 10/09/2013 | 19/05/2014 |
| Robert Klupacs | Managing Director, CEO | 01/03/2008 | 03/12/2013 |
| Don Clarke | Non Exec Director | 01/09/2005 | 29/11/2013 |
| Steven Zammit | CFO | 25/02/2013 | 10/09/2013 |
| Susan Madden | CFO | 14/05/2010 | 28/02/2013 |
| Errol Malta | Non Exec Director | 20/08/2009 | 01/10/2012 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
